Earlier this month at the J.P. Morgan Healthcare Conference, Regeneron got its Eylea sales news out of the way. | For the ...
In this week’s episode of “The Top Line,” Fierce checks in with professional services juggernaut KPMG on the biopharma ...
AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the ...
On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley, rounding out the quartet of plants it promised during its “Lilly in America” ...
Quarter after quarter for the past year, Takeda’s revenues have been bogged down by generic impacts to its stalwart ADHD med ...
Quince Therapeutics’ novel method of delivering steroids in a patient’s own red blood cells has turned out to be a bust in ataxia-telangiectasia (A-T), a rare inherited disorder. | Quince Therapeutics ...
The next stop in Vetter Pharma’s long-term growth strategy takes the German CDMO back to its home country, where it will devote approximately 480 million euros ($574.3 million) to the first constru | ...
Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...
The comments come as Sanofi reported Thursday that its total vaccine sales fell 2.5% in the fourth quarter and 1.2% for the ...
Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA ...
Last year, Novartis debuted its first-ever Super Bowl ad with an aim of starting “a movement” around early breast cancer ...
Last year, Hims & Hers put out a Super Bowl ad—the first for the telehealth giant—that sparked both support and outrage for the way it claimed that Big Pharma prices GLP-1s “ for profits, not patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results